Drug Profile

Fc-saxatilin - Celltrion/Yonsei University Health System

Latest Information Update: 28 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yonsei University Health System
Class Antiplatelets; Disintegrins; Immunoglobulin Fc fragments; Recombinant fusion proteins; Snake venoms; Thrombolytics
Mechanism of Action Integrin alphaVbeta3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Stroke

Most Recent Events

28 Mar 2021 No recent reports of development identified for preclinical development in Stroke in South Korea
31 May 2018 Celltrion enters into an agreement with Yonsei University Health System to jointly develop and license-in of Fc-Saxatilin for Ischaemic stroke

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com